Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy.
Hypertension produces pathophysiological changes that are often responsible for the mortality associated with the disease. However, it is unclear whether normalizing blood pressure (BP) with conventional therapy is effective in reversing the pathophysiological damage. The duration and initiation of treatment, site of administration, and agent used all appear to influence the reversal of the pathophysiological alterations associated with hypertension. We have previously established that retrovirally mediated delivery of angiotensin II type 1 receptor antisense (AT1R-AS) attenuates the development of high BP in the spontaneously hypertensive (SH) rat model of human essential hypertension. Our objective was to determine whether this attenuation of high BP is associated with prevention of other pathophysiological changes induced by the hypertensive state. Intracardiac delivery of AT1R-AS in neonates prevented the development of hypertension in SH rats for at least 120 days. Contractile experiments demonstrated an impaired endothelium-dependent vascular relaxation (acetylcholine) and an enhanced contractile response to vasoactive agents (phenylephrine and KCl) in the SH rat renal vasculature. In addition, the voltage-dependent K+ current density, which is believed to contribute to smooth muscle resting membrane potential and basal tone, was decreased in renal resistance artery cells of the SH rat. AT1R-AS treatment prevented each of these renal vascular alterations. Finally, AT1R-AS delivery prevented the pathological alterations observed in the SH rat myocardium, including left ventricular hypertrophy, multifocal fibrosis, and perivascular fibrosis. These observations demonstrate that viral-mediated delivery of AT1R-AS attenuates the development of hypertension on a long term basis, and this is associated with prevention of pathophysiological changes in SH rats.
Martens
J R
JR
Department of Physiology, College of Medicine, University of Florida, Gainesville, FL 23610, USA.
Reaves
P Y
PY
Lu
D
D
Katovich
M J
MJ
Berecek
K H
KH
Bishop
S P
SP
Raizada
M K
MK
Gelband
C H
CH
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001794:Blood Pressure; D006332:Cardiomegaly / Q000517:prevention & control; D003331:Coronary Vessels / Q000473:pathology / Q000502:physiology / Q000503:physiopathology; D016373:DNA, Antisense; D005355:Fibrosis; D015316:Genetic Therapy; D005822:Genetic Vectors; D006321:Heart / Q000502:physiology* / Q000503:physiopathology*; D006352:Heart Ventricles; D006801:Humans; D006973:Hypertension / Q000235:genetics / Q000503:physiopathology* / Q000517:prevention & control*; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology; D009206:Myocardium / Q000166:cytology / Q000473:pathology; D010656:Phenylephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin / Q000235:genetics*; D012077:Renal Artery / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D012190:Retroviridae
D016373:DNA, Antisense; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin; D010656:Phenylephrine; D011189:Potassium Chloride; D000109:Acetylcholine